News - Onconova Therapeutics, rigosertib


Popular Filters

Onconova drops Ph III trial of rigosertib in pancreatic cancer


US biopharma company Onconova Therapeutics says it has discontinued the Phase III ONTRAC study of intravenous…

OncologyOnconova TherapeuticsPharmaceuticalResearchrigosertib

Onconova could file NDA for cancer drug rigosertib next year

Onconova could file NDA for cancer drug rigosertib next year


Analysts at Edison Equity Research have indicated that US biopharma company Onconova Therapeutics (Nasdaq:…

FinancialOncologyOnconova TherapeuticsPharmaceuticalResearchrigosertibUSA

Pivotal drivers for prescribing metastatic pancreatic cancer drugs: report


The effect on key efficacy endpoints, primarily the effect of an emerging therapy on overall survival,…

AbraxaneBiotechnologyCelgeneEli LillyEuropeGemzarMarkets & MarketingNorth AmericaOncologyOnconova TherapeuticsPharmaceuticalrigosertib

GVK Biosciences and Onconova in cancer drug development deal


GVK Biosciences, a Hyderabad, India-based contract research and development organization, and privately-held…

Ex-RADGVK BiosciencesON-013105OncologyOnconova TherapeuticsPharmaceuticalResearchrigosertib

Baxter in up to $565 million deal with Onconova for rigosertib


US companies Baxter International (NYSE: BAX) and privately-held biotech Onconova Therapeutics have entered…

Baxter InternationalEstybonEuropeLicensingOncologyOnconova TherapeuticsPharmaceuticalrigosertib

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top